FAM178B

Across TCGA pan-cancer cohorts, FAM178B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM178B data layer compared with 24 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher FAM178B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM178B expression acts as an unfavorable survival marker.

SCLC, KICH, and STAD are the cancer types where FAM178B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
STAD	OS	Median	All	0.222	0.729	.004	12	view →
OV	DFS	Median	All	0.132	0.541	.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAM178B–SCLC (OS)

Open the SCLC breakdown →